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Summary  
Following liver injury, regeneration occurs through self-replication of hepatocytes. In 
severe liver injury, hepatocyte proliferation is impaired, a feature of human chronic liver 
disease1,2. It is contested whether other liver cell types can regenerate hepatocytes3–5. 
Here, we use two independent systems to impair hepatocyte proliferation during liver 
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injury to evaluate the contribution of non-hepatocytes to parenchymal regeneration. 
Firstly, loss of β1-Integrin in hepatocytes with liver injury triggered a ductular reaction 
of cholangiocyte origin, and ~25% of hepatocytes being derived from a non-hepatocyte 
origin. Secondly cholangiocytes were lineage traced with concurrent inhibition of 
hepatocyte proliferation by β1-Integrin knockdown or p21 over-expression, resulting in 
the significant emergence of cholangiocyte derived hepatocytes. We describe a model 
of combined liver injury and inhibition of hepatocyte proliferation that causes 
physiologically significant levels of regeneration of functional hepatocytes from biliary 
cells.  
 
Main Text  
The identification of a liver stem or progenitor cell remains elusive6. Transplanted biliary 
progenitors can partly repopulate the liver’s hepatocyte population7,8 but it is still unproven 
whether endogenous biliary cells can regenerate hepatocytes3,4. Severe liver injury in human 
and animals impairs hepatocyte proliferation and causes ductular reactions (DR) to 
emerge2,9,10. DRs may arise from the biliary epithelium11,12 or via de-differentiation of 
hepatocytes13. Biliary cells in zebrafish models have been shown to regenerate the liver after 
massive hepatocytes loss9, however, this remains unproven in mammalian systems3,4,14. 
Lineage tracing of biliary DRs into new hepatocytes, in the mouse, is dependent on both the 
severity and type of liver injury model, which have shown an inconsistent and limited 
contribution to hepatocyte regeneration3,4,15,16. Murine lineage tracing experiments, do not 
typically recapitulate human disease, as significant hepatocyte replication is seen alongside 
DRs. We therefore sought to develop a model in which DRs occur on the background of 
impaired hepatocellular regeneration and evaluate the regenerative capacity of the DRs. 
 
We lineage traced hepatocytes using the highly efficient viral AAV8.TBG.Cre injected into a 
R26RLSLtdTomato mouse, thereby activating tdTomato (tdTom) expression in over 99.5% of 
hepatocytes (Extended Data Fig. 1a,b).  These mice had either wild type Itgb1 (β1-IntegrinWT), 
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or mutated Itgb1 (β1-Integrinfl/fl) (Extended Data Fig. 1c-e), previously shown to eliminate β1-
Integrin expression17, thereby inhibiting hepatocyte growth factor signalling and impairing 
regeneration18.  
 
AAV8.TBG.Cre mediated β1-Integrin ablation caused parenchymal damage with raised serum 
markers and cytoplasmic localisation of High Mobility Group Box 1 protein (HMGB1), a DAMP 
associated with liver necrosis and inflammation 19 (Extended Data Fig. 2a,b, arrows). There 
was a prominent DR in β1-Integrinfl/fl livers compared to control β1-IntegrinWT livers, with 
increased biliary cytokeratin 19 positive (CK19pos) cells and alpha smooth muscle actin 
positive (αSMApos) myofibroblasts. CK19pos cells were distributed throughout the parenchyma 
(Extended Data Fig. 2c,d,e). β1-Integrinfl/fl livers had small areas of tdTom negative (tdTomneg) 
hepatocytes adjacent to the portal tracts (Extended Data Fig. 2c,f). Furthermore, β1-Integrinfl/fl 
livers contained more Ki67 positive hepatocytes (proliferating marker) and more p21pos 
hepatocytes (cell cycle arrest marker) (Extended Data Fig. 2g,h).  
 
We damaged β1-IntegrinWT and β1-Integrinfl/fl livers with 3 independent regimes; DDC diet, a 
model of cholestatic liver disease; Methionine and Choline Deficient (MCD) diet, a model of 
non-alcoholic steatohepatitis and thioacetamide (TAA), a model of liver fibrosis20 and studied 
the regenerative dynamics (Fig. 1a). After DDC injury, all mice lose weight but β1-Integrinfl/fl 
mice had delayed weight recovery. β1-Integrinfl/fl mice had prolonged hepatocellular Ki67 and 
p21 expression; and elevated serum markers of liver injury (Extended Data Fig. 3a-d) 
indicating that following β1-Integrin loss hepatocytes are unable to regenerate the injured liver 
efficiently. Hepatocyte Ki67 and p21 expression was rarely co-localised (Extended Data Fig. 
3e). β1-Integrinfl/fl livers had increased liver necrosis and recovered slowly from DDC injury 
(Extended Data Fig. 3f,g, asterisks). There were increased DRs following hepatocyte β1-
Integrin loss, demonstrating that the DDC induced injury remains unresolved in the absence 
of hepatocyte β1-Integrin (Fig. 1b). Persistent DRs were also found in β1-Integrinfl/fl livers that 
were injured with MCD and TAA (Fig. 1c). Following hepatocyte β1-Integrin loss DDC induced 
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DRs had atypical biliary cells, not confined to luminal structures (Fig. 1e, arrowheads and 
Extended Data Fig.4a, arrows). DRs in β1-Integrinfl/fl livers were surrounded by αSMApos, 
myofibroblasts that peaked in number by day 7 recovery, however, the degree of fibrosis 
increased throughout recovery (Fig. 1d,e and Extended Data Fig. 3h,i).  
 
To determine if non-hepatocytes regenerated hepatocytes we examined tdTom expression. 
Following liver injury and recovery with DDC, MCD and TAA, 20-30% of CYP2D and HNF4α 
(mature hepatocyte markers) positive hepatocytes were tdTomneg (Fig. 1f-h and Extended data 
Fig. 4a,b). Small, proliferative tdTomneg hepatocytes were identified from day 7 and increased 
significantly until day 14 (Extended data Fig. 4c-e). tdTomneg hepatocytes were normally found 
adjacent to SOX9pos and CK19pos ductal cells, and the number of tdTomneg hepatocytes 
decreased with distance from DRs (Fig. 2a,b). SOX9pos/tdTomneg/HNF4αpos cells could be seen 
at the border between unlabelled parenchyma and DRs (Fig. 2a), and putatively represent an 
intermediate cell state between ductular cells and hepatocytes. At day 14 of recovery tdTomneg 
hepatocyte patches had formed nodules; remaining tdTompos hepatocytes were arranged 
around glutamine synthetase (GS) positive central vein hepatocytes (Extended data Fig. 4f,g). 
The distribution of tdTomneg hepatocytes suggested a ductular origin, we therefore genetically 
labelled biliary cells and concurrently supressed Itgβ1 expression specifically in hepatocytes 
with lipid coated RNAi nanoparticles18,21 (Fig. 2c). The CK19CreERTtdTomatoLSL lineage-tracing 
model specifically labels the biliary epithelium with a 40% recombination efficiency, and 
stringently excludes the hepatocyte lineage (Extended data Fig. 5a,b). Following β1-Integrin 
RNAi treatment and DDC or MCD injury, cholangiocyte derived periportal E-
cadherinpos/tdTompos/HNF4α hepatocytes were detected compared to RNAi controls (Fig.2d). 
  
In humans, increased expression of p21 in hepatocytes is seen in chronic liver disease, 
suggesting that hepatocyte replicative potential becomes exhausted1,2. We sought to 
reproduce this in our mouse models of liver injury and regeneration by impairing hepatocyte 
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proliferation to mobilize a traceable, biliary-derived hepatocyte regenerative response. To 
achieve this we utilized a p21 coding region inserted into an AAV8 vector downstream of a 
Thyroxine Binding Globulin (TBG) promoter22 to overexpress p21 in hepatocytes (Fig 3a). 
Liver Cdkn1a mRNA expression was 6 times higher in the AAV8-p21 injected group (Fig 3b) 
Hepatocyte p21 expression was observed after injection of the AAV8-p21 (Fig 3c). Liver 
histology remained normal (Extended Data Fig. 6a,b). Proliferating non-parenchymal cells 
were seen close to the portal tracts (Fig 3d).  Additionally, no significant changes in DR or 
collagen deposition were detected following p21 over expression (Extended Data Fig. 6c,d). 
To confirm that p21 overexpression was sufficient to inhibit hepatocyte proliferation, we 
induced acute liver injury post AAV8 injection (Fig. 3e). Ki67pos/HNF4αpos hepatocytes were 
only present in mice that received the AAV8-ctrl vector (Fig. 3f), and p21 expression was 
increased in the AAV8-p21 group (Fig 3f,g). No significant changes in necrotic area was 
observed (Fig 3h), although serum transaminases were higher in the AAV8-p21 group (Fig 
3i).    
 
To induce DRs on the background of impaired hepatocyte proliferation we used the Choline 
Deficient Ethionine supplemented (CDE) Diet combined with AAV8-p21 or AAV8-ctrl 
(Extended Data Fig. 7a). Hepatocyte proliferation was inhibited in mice in the AAV8-p21 group 
(Extended Data Fig. 7b,d). Proliferating cells observed in the AAV8-p21 injected group were 
HNF4αneg (Extended Data Fig. 7c). After CDE injury, there was a trend to increased DRs in 
the AAV8-p21 group (Extended Data Fig. 7e). The AAV8-p21 group had persistent 
hepatocellular p21 expression 2 weeks after injury compared to control (Extended Data Fig. 
7f). mRNA analysis showed a 5-fold increase in p21 expression and liver damage related 
genes such as Igfbp1 and Tgfb1 increased 20-fold and 2-fold respectively. In addition, a 4-
fold increase in the DR gene Krt19 was found (Extended Data Fig. 7g). Together, these 
findings demonstrate that AAV8-p21 administration causes hepatocyte p21 accumulation and 
impaired hepatocyte proliferation following injury. 
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We used the CK19CreERTtdTomatoLSL lineage-tracing model to test whether cholangiocytes 
gave rise to hepatocytes in various diet induced liver injuries combined with p21 over 
expression (Fig 4a). After the CDE, MCD, or DDC injury regimes (Fig.4a, Extended Data Fig. 
8a,f), tdTom expressing hepatocytes were observed in the AAV8-p21 group (Fig4b, Extended 
Data Fig. 8 b,c,g,h). tdTompos cells contributed to 6.12 ± 0.3% of the liver 2 weeks after injury 
(Fig.4b). Considering that the Krt19CreERTtdTomatoLSL system labels approximately 40% of all 
biliary cells we corrected for this limitation in recombination efficiency, predicting that biliary 
cells differentiate into approximately 15.3 % of hepatocytes in this model. Periodic acid–Schiff 
staining of serial liver sections show the tdTompos hepatocytes store glycogen (Fig 4c). Other 
hepatocyte markers such as HNF4α, GS, and CYP2D were expressed by these cholangiocyte 
derived tdTompos hepatocytes (Fig 4d, Extended Data Fig 8d,i and 9a). These cholangiocyte 
derived hepatocytes were present 10 weeks after injury (Extended Data Fig 9 b,c,d,e). 
Periportal tdTompos, SOX9neg hepatocytes were adjacent to the tdTompos, SOX9pos DRs 
suggesting differentiation of SOX9pos ductular cells into hepatocytes (Fig. 4e, Extended Data 
Fig 8e). tdTompos hepatocytes expressing HNF4α and zone 1 marker E-Cadherin were directly 
adjacent to the tdTompos and PanCKpos cholangiocytes in keeping with their ductular origin 
(Fig. 4f). To test the proliferative capacity of the cholangiocyte derived tdTompos hepatocytes, 
we performed 50% partial hepatectomy following MCD injury/recovery (Extended Data Fig. 
9f). Fewer hepatocytes in AAV8-p21 group were proliferative following hepatectomy 
(Extended Data Fig 9g) and periportal tdTompos Ki67pos E-Cadherinpos proliferating hepatocytes 
were observed in the AAV8-p21 group (white arrows) (Extended Data Fig. 9h). These results 
confirm the direct contribution of labelled cholangiocytes to hepatocyte regeneration during 
injury when hepatocyte proliferation is inhibited. To compare hepatocytes of different origins, 
we isolated: non-hepatocyte derived hepatocytes from the β1-Integrinfl/fl model (tdTomneg), 
cholangiocyte derived hepatocytes from the AAV8-p21 model (tdTompos) (Extended data 
Fig.10a-c) and compared against hepatocytes and cholangiocytes from injured wild-type mice. 
Gene expression between these cells was assessed with a drug metabolism qPCR array and 
RNAseq. Global transcriptional states of the biliary derived hepatocytes from AAV8-p21 
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treated livers and tdTomneg hepatocytes from the β1-Integrinfl/fl model were highly similar to 
hepatocytes and distinct from ductal cells (Fig. 4g, Extended Data Fig. 10d,e,f). tdTompos 
hepatocytes clustered closely with control wild-type hepatocytes (Fig. 4h). Differences in the 
newly formed tdTomneg hepatocytes from the β1-Integrinfl/fl model may be explained by the 
continued presence of defective β1-Integrinfl/fl hepatocytes in the liver and their effect upon the 
tissue microenvironment (Extended Data Fig. 10e,f ). 
 
Impaired hepatocyte regeneration has been studied in two independent systems; hepatocyte 
β1-Integrin ablation, and p21 over-expression. Both models triggered DRs followed by  
clusters of cholangiocyte derived hepatocytes. Multiple hepatocyte sub-populations have been 
suggested as regenerative under homeostasis23,24 or liver injury14. However, our findings show 
that whilst DRs can be generated following injury, impaired hepatocyte regeneration is 
required for cholangiocytes to form hepatocytes. The mechanism of effect of the two models 
is different: β1-Integrin ablation causes hepatocyte necrosis, p21 expression and inhibition of 
growth factor signalling,18 and viral p21 overexpression directly inhibits hepatocyte 
proliferation; the common factor being impaired hepatocyte regeneration. This explains 
previous conflicting data from mouse, rat and human disease, where the lack of differentiation 
seen in lineage tracing models is likely due to ongoing effective hepatocyte mediated 
regeneration. The full potential of cholangiocyte derived hepatocyte regeneration may be 
higher as these are short term injury models compared to human liver disease. These systems 
have now identified the cellular sources of regeneration in severely injured adult liver. This will 
facilitate studies into the signals controlling this regenerative pathway, aiding the development 
of liver regeneration therapies.  
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Figures and figure legends  
 
Figure 1. Hepatocyte β1-Integrin ablation combined with liver injury amplifies ductular 
reaction and hepatocytes regenerate from a non-hepatocyte source. 
a, Experimental strategy to stimulate liver regeneration with hepatotoxic agents. b-d, 
Quantification of CK19pos cells or αSMApos cells; before, during and after injury (N=6 DDC, 
N=≥3 MCD and N=≥2 TAA). e, Confocal CK19/αSMA immunofluorescence; invasive biliary 
cells(arrowheads), ducts with lumens(arrows). f,h, Quantification of tdTompos/HNF4αpos 
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hepatocytes before, during and after injury (N=6 DDC, N=3 ≥MCD and N=≥2 TAA). g Confocal 
tdTom immunofluorescence of CYP2D and HNF4α hepatocytes. PFV-per field of view. Scale 
bars:100µM. Data are mean ± s.e.m.; * P=<0.05; ** P=<0.01; *** P=<0.001; 2way ANOVA, 
Bonferroni post-tests. 
 
Figure 2. Non-hepatocyte derived hepatocytes originated from the portal tract, 
Keratin19 biliary lineage tracing confirmed their ductal origin.  
a, tdTom /HNF4α/CK19 and tdTom/HNF4α/Sox9 immunofluorescent confocal images at day 
7 recovery post DDC diet. tdTomneg hepatocytes(HNF4αpos) adjacent to CK19pos and Sox9pos 
ductular reactions(white arrows) and rare tdTomneg hepatocytes Sox9pos/HNF4αpos(yellow 
arrows). b, Quantification of tdTomneg/HNF4αpos hepatocytes adjacent to the CK19pos DRs post 
DDC injury; N=8. c, Experimental strategy to lineage trace biliary epithelial cells on a 
background of liver injury and hepatocyte Itgβ1 silencing. d, Immunofluorescent confocal 
images and immunohistochemistry 14 days after DDC and MCD diet combined with RNAi 
mediated β1 Integrin or luciferase mRNA suppression, bile ducts(arrowheads). N=4. Scale 
bars:100µM Data are mean ± s.e.m. 
 
Figure 3. Inhibition of hepatocyte proliferation following AAV8-p21 injection. 
a, Schematic representing the AAV8-p21 construct. b, Cdkn1a whole liver RNA expression 
after AAV8 injection. N=3 c, p21 immunohistochemistry of AAV8 injected mice. d, Ki67 
immunostaining of AAV8 injected livers.  e, Experimental design of the AAV8-p21 with CCl4 
regime. f, Ki67/HNF4α immunofluorescence following AAV8 and CCl4 injection, upper panel. 
p21 immunohistochemistry following CCl4 injection. g, Quantification of Ki67pos hepatocytes in 
mice injected with CCl4 after AAV8 injection. h, Necrotic area 48-hours post CCl4 injection I, 
Mouse serum ALT and AST after CCl4. Scale bars:100µM. Data are representative of 1-2 
independent experiments. N=4 Data are shown as mean ± s.e.m. Mann-Whitney U-test 
*P < 0.05.  
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Figure 4. Emergence of ductular derived hepatocytes following chronic liver injury 
when hepatocyte proliferation is impaired. 
a, Schematic of the MCD/recovery injury diet regime. b, tdTom immunohistochemistry on 
Krt19CretdTomatoLSL livers following MCD recovery regime. High magnification images and 
quantification of tdTom positive cells (insets) N=4. c, Immunostaining of tdTom and Periodic 
acid-Schiff staining on serial liver sections of AAV8 injected mice. d, Immunofluorescent 
double staining of HNF4α (green, upper panel), Glutamine Synthetase (green, middle panel), 
CYP2D (bottom, lower panel) and tdTom (red). e, Double Immunohistochemistry of tdTom 
(red), and SOX9 (green, upper panel), PanCK (green, lower panel). f, Confocal images of 
serial liver sections of AAV8 injected mice. tdTomato (red), HNF4α (green, left panel), PanCK 
(green, right panel), E-cadherin (grey). g,h, Pearson’s correlation plot with hierarchical 
clustering and 3D Principal Component Analysis (PCA) for total transcriptional landscapes 
N=3. Scale Bars:100µM. Data are representative of 1–2 independent experiments. N=4 Data 
are shown as mean ± s.e.m. Mann-Whitney U-test, *P < 0.05.  
 
Extended Data Figure 1. AAV8.TBG.Cre labelled and deleted β1-Integrin in 99.5% of 
hepatocytes. 
 a, tdTom, biliary specific cytokeratin 19 (CK19) and hepatocyte specific HNF4α 
immunofluorescence in AAV8.TBG.Cre/null treated livers 2 weeks post AAV administration. 
Cre treated HNF4αpos hepatocytes are tdTompos in contrast to the null treated; CK19pos ductal 
cells are located at the portal tract (PT), confocal images. b, Liver tissue analysis quantifying 
tdTompos, HNF4αpos hepatocytes 2 weeks post AAV8.TBG.Cre/null administration, 
AAV8.TBG.Cre N=7, AAV8.TBG.null N=3. c, Hepatocellular β1-Integrin immunofluorescence 
grayscale image and dual image with membranous β-catenin, 2 weeks post AAV8.TBG.Cre 
administration, arrows identify β1-Integrin in the hepatocyte cell membrane, arrowheads 
identify non-parenchymal β1-Integrin staining; confocal images. d, 2 weeks post 
AAV8.TBG.Cre administration; whole liver β1-Integrin Western Blot. e, 2 weeks post 
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AAV8.TBG.Cre administration; whole liver QPCR for β1-Integrin, N=3. Scale bars: 100µM. 
Data are mean ± s.e.m.; two-tailed unpaired t-test; * P=0.05.  
 
Extended Data Figure 2. Ablation of β1-Integrin caused liver damage, ductular reaction 
and small patches of un-labelled periportal hepatocytes. 
a, Serum ELISA for markers associated with liver function 9 weeks post AAV8.TBG.Cre 
administration; N=3. b, 9 weeks post AAV8.TBG.Cre administration; anti-HMGB1 DAB 
immunohistochemistry. Arrowheads identify nuclear HMGB1, arrows highlight cytoplasmic 
HMGB1. c, 9 week post AAV8.TBG.Cre; α smooth muscle actin (αSMA)/CK19, tdTom/HNF4α 
and glutamine synthetase (GS)/tdTom immunofluorescence, arrows point to areas with DR. 
d, Liver tissue analysis quantifying CK19pos cells 9 weeks post AAV8.TBG.Cre administration; 
N=3. e, Liver tissue analysis quantifying αSMApos cells 9 weeks post AAV8.TBG.Cre 
administration; N=3. f, Liver tissue analysis quantifying tdTompos, HNF4αpos hepatocytes in 
livers 9 weeks post AAV8.TBG.Cre administration; N=3. g, Liver tissue analysis quantifying 
Ki67pos, HNF4αpos hepatocytes 9 weeks post AAV8.TBG.Cre administration; N=3. h, Liver 
tissue analysis quantifying p21pos, HNF4αpos hepatocytes 9 weeks post AAV8.TBG.Cre 
administration; N=3. Scale bars: 100µM. Data are mean ± s.e.m.; two-tailed unpaired t-test; * 
P=0.05, ** P=0.01. 
 
Extended Data Figure 3. Hepatocyte β1-Integrin deletion delayed and altered the 
regenerative response after treatment with the liver injury diet DDC. 
 a, DDC diet and recovery; serum ELISA for markers associated with liver function, N≥5. b 
Body weight measurements during DDC diet and the subsequent recovery; N=≥5. c, Liver 
tissue analysis quantifying prolonged Ki67pos/HNF4αpos hepatocytes after DDC injury; N=≥5. 
d, Liver tissue analysis quantifying p21pos/HNF4αpos hepatocytes after DDC injury; N=≥5, and 
representative p21/HNF4α immunofluorescence in samples 7 days after DDC injury. e, 
p21/Ki67 immunofluorescence 7 days after DDC injury. f, Representative Haematoxylin & 
Eosin (H&E) histochemical stain of sections after DDC injury; asterisks highlight necrotic 
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areas; arrows highlight small cellular infiltrate. g, Morphometric quantification of necrotic area 
from H&E sections in DDC treated samples at peak injury and recovery.  h, fibrosis analysis, 
percentage of pixels PicroSirius Red (PSR) positive, before, during and after DDC injury; 
N=≥5. i, Representative images of PSR histochemistry on samples from day 42 of recovery 
after DDC diet.  Scale bars: 100µM. Data are mean ± s.e.m.; two-tailed unpaired t-test; 2way 
ANOVA, Bonferroni post-tests. * P=<0.05, ** P=<0.01, *** P=<0.001. 
 
Extended Data Figure 4.  β1-Integrin ablation and DDC induced injury resulted in large 
areas of tdTomneg hepatocytes. 
a, tdTom/CK19 immunofluorescence, tiled images of β1-Integrinfl/fl and β1-Integrin WT livers 
after DDC diet and 14 days of recovery. (1-4) Enlarged regions of interest; (1) invasive CK19 
positive cells (arrows), (2) tdTom negative regenerative nodule, (3, 4) fully recovered β1-
Integrin WT liver with typical biliary ducts (arrowheads). b, Separate channels from a merged 
CYP2D and tdTom immunofluorescent confocal image in Fig 1g, showing CYP2D expression 
between tdTompos and tdTomneg hepatocytes. c, d and e, Liver tissue analysis and a 
representative PCNA/HNF4α/tdTom immunofluorescent image in β1-Integrinfl/fl mice at day 14 
recovery post DDC injury; quantifying PCNA expression and nucleus size in both tdTompos and 
tdTomneg hepatocytes (HNF4αpos); N=8. f, Liver tissue analysis in β1-Integrinfl/fl mice at day 14 
recovery post DDC injury; quantifying tdTompos HNF4αpos hepatocytes adjacent to the GSpos 
CV. N=8. g, tdTom/GS/CK19 immunofluorescence in mice at day 14 recovery post DDC diet, 
β1-Integrinfl/fl liver has patches of tdTomneg hepatocytes connected to CK19pos biliary 
epithelium, tdTompos hepatocytes remain arranged around the GSpos central veins (CV). 
Data are mean ± s.e.m.; ** P=<0.01, paired t-test. 
 
Extended Data Figure 5. K19CreERTtdTomatoLSL strictly labels 40% of the biliary 
epithelium. 
Three X 4mg doses of tamoxifen followed by a 14day wash out period. a. Representative 
images of CK19/tdTom dual immunofluorescence. b.  Quantification of CK19pos biliary 
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epithelial cells which are tdTomato positive N=7. Scale Bars: 100µM. Data are shown as mean 
± s.e.m. 
 
Extended Data Figure 6. Analysis of AAV8-p21 injected livers. 
 
a. Schematic showing the experimental design of the AAV8-p21 injection. b. Haematoxylin 
and Eosin staining on the livers of AAV8 injected mice. c. Quantification and representative 
images of immunostaining for PanCKpos cells of the AAV8 vectors injected liver. d. Picro 
Sirius Red analysis of the AAV8 vectors injected livers. Scale Bars: 100µM. N=5, Data are 
shown as mean ± s.e.m. Mann-Whitney U-test, *P < 0.05 
 
Extended Data Figure 7. Analysis of AAV8-p21 injected livers following CDE injury 
regime. 
.a.. Schematic representation of the CDE recovery regime. b. Immunostaining of Ki67 (red), 
HNF4α (green) on AAV8 injected mice during CDE injury. White arrows denote Ki67 and 
HNF4α double positive hepatocytes. c. Split channel images of DAPI, Ki67, and HNF4α on 
liver sections of AAV8-p21 injected mice following CDE injury. d. Ki67 (red) and HNF4α 
(green) immunohistochemistry of the liver of mice injected with AAV8-p21 and control 2 
weeks after CDE injury. . e. PanCK immunohistochemistry and quantification of PanCKpos 
cells of the liver of AAV8 injected mice during and 2 weeks after CDE diet induced injury. f. 
p21 immunohistochemistry on AAV8 injected mice during and after CDE injury. Insets 
showing high magnification images. g. Whole liver Cdkn1a, Igfbp1, Tgfb1, Krt19 mRNA 
expression of AAV8 vectors injected mice 2 weeks following CDE injury. Scale Bars: 100µM. 
N=4, Data are shown as mean ± s.e.m. Mann-Whitney U-test, *P < 0.05 
 
Extended Data Figure 8. Analysis of the Krt19CretdTomatoLSL mice which received AAV8-
p21 injection followed by DDC or CDE recovery regime.  
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a. Schematic showing the experimental design of the AAV8-p21 injection followed by DDC 
recovery regime. b,c. tdTom staining of Krt19Cre tdTomatoLSL mice that received AAV8-p21 
injection followed by DDC recovery regime. d. HNF4α (Green) and tdTom (red) staining on 
the Krt19CretdTomatoLSL mice that received AAV8 injections and treated with the DDC recovery 
regime. e. SOX9 (Green) and tdTom (red) staining on the Krt19Cre tdTomatoLSL mice that 
received AAV8 injections and treated with the DDC recovery regime.  f. Schematic 
representation of the experimental design of the AAV8-p21 injection followed by CDE recovery 
regime. g. Epifluorescence images of the liver of the mice received AAV8-ctrl or AAV8-p21 
injections followed by the CDE recovery regime. h. Immunostaining for tdTomato of mice 
received AAV8-ctrl or AAV8-p21 injections followed by the CDE recovery regime. i. tdTomato 
(red) and HNF4α (green) immunofluorescent double staining of mice received AAV8-ctrl or 
AAV8-p21 injections followed by the CDE recovery regime. N=4, Scale Bars: 100µM. 
 
Extended Data Figure 9. Analysis of the Krt19Cre tdTomatoLSL mice which received 
AAV8-p21 injection followed by DDC or CDE recovery regime.  
a. Representative immunofluorescent images showing split channels of tdTomato, HNF4α, 
and DAPI of mice received AAV8-ctrl or AAV8-p21 injections followed by the MCD recovery 
regime. b. Schematic representation showing the experimental design of the AAV8-p21 
injection followed by a MCD long recovery regime. c,d. tdTom staining of Krt19Cre tdTomatoLSL 
mice that received AAV8-p21 injection followed by MCD long recovery regime. e. tdTomato 
(red) and HNF4α (green) immunofluorescent double staining and quantification of tdTompos 
HNF4αpos hepatocytes in that mice received AAV8-ctrl or AAV8-p21 injections followed by the 
MCD long recovery regime. f. Schematic representation of partial hepatectomy performed 
after the MCD recovery regime. g. Quantification and Immunofluorescent double staining of 
HNF4α (red), and Ki67(green) of mice received 50% partial hepatectomy. h. Confocal 
microscopy images of mice received 50% partial hepatectomy. tdTomato (red), Ki67 (green), 
E-Cadherin (grey). N=4.  Scale Bars: 100µM. Data are shown as mean ± s.e.m. 
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Extended Data Figure 10. Comparison between ductular derived hepatocytes and 
hepatocytes regenerated through self-duplication. 
a. Experimental design to isolate wildtype hepatocytes/ducts and ductular derived hepatocytes 
from a regenerated liver. b. FACS gating strategy to isolate tdTompos and tdTomneg 
hepatocytes. c. Cytospins and tdTom/HNF4α immunofluorescence of FACS sorted cells. d. 
Visual examples of average RNA-seq transcriptional reads in sample groups across select 
loci. Scales referring to normalised read counts are displayed on the right of each plot. 
RNAseq annotated genes are plotted n black below. e. RNAseq generated Z-score heatmaps 
with hierarchical clustering across specific gene sets. Heatmaps display gene expression 
levels normalised to each gene, yellow = higher expression, blue = lower expression, N=3. f.   
qPCR array for phase 1 drug metabolism enzymes N=4. Scale Bars: 100µM. 
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Methods  
Animal models 
The animals in this study were on a C57BL6/J background. Both male and female mice were 
used. Animals were housed in a specific pathogen-free environment and kept under standard 
conditions with a 12 hour day/night cycle and access to food and water ad libitum. All animal 
experiments were carried out under procedural guidelines, severity protocols and with ethical 
permission from the University of Edinburgh Animal Welfare and Ethical Review Body 
(AWERB) and the Home Office (UK).  
 
To delete β1-Integrin in vivo, we utilised the β1-Integrinfl/fl mice (The Jackson Laboratory), this 
model has exon 3 of β1-Integrin gene is flanked by loxP sites 1. To lineage trace β1-Integrinfl/fl 
cells we crossed this strain with the R26RtdTomatoLSL mouse (The Jackson Laboratory). 
 
Genotyping was performed by the Transnetyx genotyping service. 
Mice between 7-10 weeks of age had Cre mediated recombination induced with 
AAV8.TBG.Pi.Cre.rBG (Penn vector core, CS0644). Control, null, experiments used 
AAV8.TBG.Pi.null.rBG (Penn vector core, CS0255).Viruses were administrated by tail vein 
injection at a concentration of 2.5X1011 GC/ml. AAV8 viruses were diluted in sterile PBS. Mice 
were given a 2 week wash out period before being placed on toxic injury diets. 
Small interfering RNA (siRNA) formulated in to lipidoid nanoparticles were used to silence 
Itgβ1 mRNA in vivo. These siRNA nanoparticles have been previously shown to specifically 
suppress hepatocyte β1 integrin expression2,3. 0.5mg/kg doses were administrated 
intravenously via the tail vein to each mouse every 5 days according to the schematic in Fig.2e.  
The Krt19CreTdTomatoLSL mice was induced by 3 individual i.p. injections of Tamoxifen 
(20mg/ml, Sigma UK) at the dose of 4mg. K19Cre animals received two weeks of normal diet 
after the last Tamoxifen injection before commencing an injury diet regime. 
To induce liver injury mice were given 0.1% 3,5-Diethoxycarbonyl-1,4-dihydrocollidine (DDC) 
mixed with Rat & Mouse No1 Maintenance (RM1) diet (Special Diet Services), for 7-10 days; 
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the Methionine and Choline Deficient (MCD) diet (MP Biomedicals) was given for 7-14 days; 
Thioacetamide (TAA) (Sigma Aldrich) was administered in the drinking water at a 
concentration 300mg/L for 21 days; the choline deficient ethionine supplemented (CDE) diet 
began with a choline sufficient CDE weaning diet for 1 week (MP Biomedicals, 960412) 
followed by 3 weeks of CDE diet (custom made by MP biomedicals). After injury diet mice 
were given normal chow and drinking water. For the CCL4 injury model mice received one IP 
injection of CCL4 at a dose of 1ml/Kg and were then euthanized 48 hours later.  
50% Partial Hepatectomy was carried out under isoflurane anaesthesia, median laparotomy 
was performed followed by removal of the left lateral and upper left median lobe, as previously 
described4. Mice were sacrificed at 48 hours after surgery. 
Mice were euthanized according to UK Home Office regulations. Blood was collected by 
cardiac puncture and centrifuged to collect serum. Organs were harvested and either directly 
frozen at -80°C or fixed in 10% formalin (in PBS) for 12 hours. Formalin fixed tissue was then 
stored in paraffin. Animals due to reaching experimental severity protocol boundaries were 
excluded from analysis. Otherwise all animals were included in analysis. Animal studies are 
used throughout in this work. Power calculations were not routinely performed; however 
animal numbers were chosen to reflect the expected magnitude of response taking into 
account the variability observed in previous experiments. 
 
AAV8-p21 design and in vivo delivery 
pGEM p21 was a gift from Dr Frederic Mushinski (Addgene plasmid # 8443). The p21 plasmid 
was packaged into the AAV8.TBG vector by Penn Vector Core. AAV8-Ctrl plasmid 
(AAV8.TBG.PI.Null.bGH , Cat No: AV-8-PV0148) was obtained from Penn Vector Core. 7.5 x 
1011 viral particles were reconstituted in 100µL injected intravenously through tail vein injection 
with BD Ultra-Fine Insulin Syringes.  
 
Histology, immunohistochemistry and immunofluorescence  
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Formalin fixed tissue embedded in paraffin. 4µm sections were blocked with protein block 
(Spring Bioscience) and stained overnight at 4°C using antibodies listed in Table S1. Primary 
antibodies were detected using fluorescent conjugated secondary antibodies (alexa 
488/alexa555 and alexa657; invitrogen). Sections were stained with Dapi and mounted with 
fluromount (SouthernBiotech). For DAB stained sections tissue was blocked with Bloxall 
(Vector), Avidin/Biotin block (Invitrogen) and protein block. Primary antibodies were incubated 
overnight at 4°C. Species specific secondary biotinylated antibodies (Vector), Vectastain 
R.T.U, ABC reageant (Vectar) and DAB chromogen (Dako) were used to detect the primary 
antibody. Haematoxylin counter stain was used alongside the DAB. 
When two antibodies from the same species were used, Sox9/RFP/HNF4α 
immunofluorescent stain, primary antibodies were applied sequentially. The first antibody to 
be applied, anti-RFP, was detected using a species specific secondary antibody (Dako) 
conjugated to HRP and a Perkin Elmer TSA Plus Cyanine 3, signalling amplification, kit 
(NEL744B001KT). This was followed by a second antigen retrieval to denature any antibodies 
in the tissue and prevent cross-reaction with the following antibody application.  
Heamatoxylin and Eosin (H&E) stains were automatically produced using a Shandon Varistain 
Automated Slide Stainer. PicroSirius Red (PSR) stains used reagents from Sigma Aldrich; 
picric acid Cat No:P6744-1GA, fast green Cat No:F7258-25G, direct red Cat No: 365548-25G. 
Staining was done according to manufacturer’s instructions.  
  
Table S1: Primary Antibodies for immuno-histochemistry and immunofluorescence    
Antibody Supplier Fixation 
Antigen 
retrieval  
Antibody 
concentration 
HNF4α (C-19) 
(Goat) 
SC-6556 Santa 
Cruz Formalin 
Heat mediated, 
Tris EDTA 
(pH9) 
1/50 
Sox9 (Rabbit) ab5535 Millipore Formalin 
Heat mediated, 
Tris EDTA 
(pH9) 
1/200 
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Microscopy and cell counting 
For confocal microscopy either a Leica SPE inverted microscope or a Zeiss LSM 780 confocal 
microscope were used and images were deconvoluted using Fiji ImageJ. Brightfield images 
were taken using a Nikon Eclipse e600 microscope and Retiga 2000R camera (Q-Imaging) 
and acquired with image pro premier software. PSR anaylsis used an AxioScan Z.1 (Zeiss) to 
CK19 (Troma III) 
(rat) DSHB Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/200 
Smooth Muscle 
Actin α (mouse) 
A2547 Sigma 
Aldrich Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/2000 
RFP (Rabbit) ab62341 Abcam Formalin 
Heat mediated, 
Tris EDTA 
(pH9) 
1/200 
CYP 2D (Sheep) 
Gift from R. 
Wolfe, University 
of Dundee 
Formalin 
Heat mediated, 
Tris EDTA 
(pH9) 
1/200 
mCherry (Goat) AB0081-500 SICGEN Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/200 
Glutamine 
Synthatase 
(Rabbit) 
ab73593 Abcam Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/100 
Ki67 (Rabbit) ab16667 Abcam Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/200 
P21 (Rabbit) SC-471 Santa Cruz Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/50 
PCNA (Mouse) ab29 Abcam Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/10000 
HMGB1 (Rabbit) ab18256 Abcam Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/100 
HNF4α (Rabbit) ab181604 Abcam Formalin 
Heat mediated, 
Tris EDTA 
(pH9) 
1/200 
β Catenin (Rabbit) ab2365 Abcam Frozen, methanol NA 1/200 
Integrin β1 (Rat) MAB1997 Millipore 
Frozen, 
methanol NA 1/200 
E-cadherin 
(Mouse) 
BD Biosciences  
610181 Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/500 
PanCK (Rabbit) Dako Z0622 Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/200 
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acquire tiled images at a 20X magnification. De-tiled images were then analysed using a 
standard colour threshold in Fiji Image J. Necrotic areas were quantified using haematoxylin 
and eosin (H&E) histochemistry and the trainable WEKA segmentation tool in Fiji Image J. 
Fluorescent tiled images were generated on a Perkin Elmer Operetta high content imaging 
system, subsequent image stitching was done on Fiji ImageJ using the pairwise stitching 
plugin 5. DAPI, Alexafluor 488, and 555 were detected using band paths of 415-480, 495-540 
and 561-682nm for 405, 488 543 nm lasers respectively.  
  
In cases which manual quantification was performed (including animal experiments), counts 
were performed manually on blinded slides and more than 20 consecutive non overlapping 
fields at x100 or x200 magnification. 
 
Single Cell Liver tissue analysis 
Images were acquired in up to four fluorescent channels at 10X magnification on a Perkin 
Elmer Operetta high content imaging system and subsequently analysed using the Columbus 
software.  An average of 25 images were taken per liver section. One field of view corresponds 
to 1.37mm2. Dapi stained nuclei were identified based on pixel intensity using method ‘M’ with 
approximately 7000 nuclei identified per field. Nuclear size and morphology was then 
determined. Illumination correction and background normalization was performed using the 
sliding parabola module. Depending on the experiment nuclei were then assigned as positive 
or negative based on the mean pixel intensity in the corresponding channel in either the 
nucleus (HNF4α, tdTomato, Ki67, P21 and PCNA) or a 7µm thick region surrounding the 
nucleus (CK19 and αSMA). For each experiment identical thresholds were used in all images 
for assigning nuclei to a specific population. 
 
Protein homogenates and western blots   
Protein was isolated from whole liver. Small, 1-2mm2 pieces of liver were homogenised using 
a tissue tearor (Biospec Products) and lysis buffer (lysis buffer: 150mM NaCl, 20mM Tris 
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pH7.5, 1mM EGTA, 1mM EDTA, 1% Triton X-100, 2X Protease inhibitor Cocktail(Sigma 
Aldrich)). Samples were mixed at 4°C for 30 minutes and then centrifuged for 10 minutes at 
20’000g. The aqueous supernatant was removed and the protein concentration was 
determined using a Pierce BCA Protein Assay Kit (Thermo Scientific). Proteins were 
separated using SDS-page and transferred to nitro cellulose membranes, anti-β1-Integrin 
(Millipore, MAB1997) 1/1000 and anti-β-actin (Cambridge Biosciences) 1/2000 were used to 
detect proteins.  
 
Isolation of Biliary Ducts, Hepatocytes and Fluorescence Activated Cell Sorting (FACS)  
Hepatocytes and biliary ducts were isolated using the classical perfusion protocol. Briefly, 
animals received an overdose of anaesthetic followed by laparotomy, the portal vein was 
cannulated and injected with Liver Perfusion Medium (Gibco) and Liver Digest Medium 
(Gibco). For ducts isolation, ducts were digested and isolated as previously described6. For 
hepatocyte isolation,  the liver was removed and mechanically disaggregated. The resulting 
disassociated cells were filtered through a 70µm filter (BD Biosciences). Hepatocytes were 
purified with a density gradient centrifugation7, which isolates cells with hepatocyte 
morphology and expression of CYP2D6 (a mature hepatocyte marker) at a purity over 99%8. 
Briefly, cells were layered above various Percoll solutions, 1.06, 1.08 and 1.12 g/ml Percoll 
(Sigma) in PBS. Cells were spun at 750xG 20 min. The hepatocyte layer, between the 1.08 
and 1.12 mg/ml Percoll layers, was collected for FACS. Purified Hepatocytes were sorted on 
a BD biosciences Fusion Flow Cytometer. Sorted cells where lysed and the RNA was 
extracted.  
 
RNA isolation and RT-QPCR 
Liver tissue was homogenised in Trizol (Life Technologies). Homogenates were mixed with 
chloroform (1:5 ratio Chloroform:Trizol) and centrifuged at 4°C, 1’200g, for 15 minutes. The 
aqueous supernatant was removed and mixed 1:1 with 70% ethanol. RNA was extracted using 
a Qiagen RNaesy mini kit according to the manufacturer’s instructions. Reverse Transcription 
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and Real Time-QPCR was performed using Qiagen Quantitect and Quantifast reagents on a 
LightCycler 480 II (Roche). Commercial primers from Qiagen’s Quantitect range were used; 
Cdkn1a (Qiagen QT00137053), Igfbp1 (Qiagen QT001114716), Tgfb1 (Qiagen QT00145250), 
krt19 (Qiagen QT00156667), β1-Integrin (Qiagen, QT00155855) and Peptidylprolyl isomerase 
A (PPIA) (Qiagen QT00247709). Gene expression was normalised to the house keeping gene, 
PPIA. Samples were run in triplicate. The RT2 Profiler PCR Array, Drug Metabolism: Phase I 
Enzymes was purchased from Qiagen (330231 PAMM-068Z), cDNA was synthesised from 
extracted RNA using the RT2 First stand Kit (Qiagen; 330401) according to the manufactures 
instructions. The RT2 Profiler PCR Array was run on a Roche LightCycler 480 II with RT2 SYBR 
Green qPCR Mastermix (Qiagen; 330500), according to the manufactures instructions. 
Analysis were performed according to manufacturer’s templates and guidelines. 
 
Whole Genome RNA sequencing 
Samples were treated with DNase (Ambion), and sample integrity verified on the Agilent 
Bioanalyser with the RNA Nano chip.  Illumina Tru-seq paired end strand specific sequencing 
(Illumina, USA) was carried out on a NextSeq-550 sequencer (Edinburgh Clinical Research 
Facility, Western General Hospital, Edinburgh, Scotland, UK). 500ng of Total RNA underwent 
ribosomal RNA depletion (rRNA) prior to purification, fragmentation, random hexamer cDNA 
generation and purification with AMPure XP beads (Beckman-Coulter, USA). Multiple indexing 
adapters were ligated to ds cDNA with subsequent hybridisation onto flow cells, and DNA 
fragment enrichment by 15 cycle PCR for sequencing.  Completed libraries were quantified 
by qPCR using the KAPA Illumina Library Quantification Kit (Illumina, USA) before multiplexing 
in two equimolar pools and running on two flow cells on the Illumina NextSeq 550. The 
resulting FastQ files were mapped to the reference genome (mm9) using the Tophat alignment 
tool (V2) on Illumina Basespace software and reads per kilobase per million (RPKM) scores 
calculated for each gene.  Differential gene expression was carried out using DEseq with cut 
offs of Log2 fold change >2 and adjusted P values <0.05 within replicates applied. Global 
analysis of total RPKM datasets to assess overall transcriptional states was carried out by 
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calculating and plotting Pearson’s correlation scores visualized as a heat map with Euclidian 
and Ward clustering applied. PCA plots were also carried out with the use of Illumina 
Basespace software. Plots for Pearson’s correlation scores with hierarchical clustering were 
also carried out on all genes displaying significant gene expression changes relative to the 
control set. Visual examples of the transcriptional data were generated by calculating the 
average expression per group (control, β1 integreinfl/fl , AAV8-p21 & Biliary Duct ) and loading 
onto the Broad Institute’s Integrative Genomics Browser 
(https://software.broadinstitute.org/software/igv/download). RPKM values for select gene sets 
(hepatocyte, biliary, Notch signaling and Wnt signaling) were also clustered by Euclidian and 
Ward methods and expression patterns visualized by plotting as a Z-score heatmap with row 
normalized values. Data files can be accessed through GEO, with the following accession 
number GSE98034. 
 
Statistical Analysis 
Prism software (GraphPad Software, Inc) was used for all statistical analysis.  Data is 
presented as mean ± s.e.m. n refers to biological replicates. Normal distribution of data was 
determined using D‘Agostino and Pearson omnibus normality test. For parametric data, data 
significance was analysed using a two-tailed unpaired Students t-test. In cases where more 
than two groups were being compared, then a one-way ANOVA was used. In cases where 
two groups were split between two independent variables a two-way ANOVA was used. In 
instances where the n was too small to determine normal distribution or the data was non-
parametric then a two-tailed Mann Whitney U-test was used. F tests were used to compare 
variances between groups. 
In cases which randomisation was used (including animal studies), samples were randomized 
by a 'blinded' third party before being assessed separate 'blinded' assessor. Unblinding was 
performed immediately prior to final data analysis. 
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Serum analysis 
Serum analysis used commercial kits according to the manufacturer’s instructions; alanine 
transaminase, albumin, bilirubin (Alpha Laboratories); aspartate aminotransferase and 
alkaline phosphatase (Randox laboratories). All kits were adapted for use on a Cobas Fara 
centrifugal analyser (Roche).  
 
Reproducibility of experiments 
Routinely qPCR experiments were performed in technical triplicates of multiple biological 
replicates. For representative images whole liver lobes were examined histologically in 
multiple biological replicates. 
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